ReviewFrontiers in endocrinology2022
Metabolic Syndrome-Related Kidney Injury: A Review and Update.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed.
- Changes in urinary albumin levels with dotinurad oral administration in hyperuricemic patients with microalbuminuria: a post hoc analysis.Clinical and experimental nephrology · 2025Trial
- The onset of hypertension in metabolic syndrome is independent of renal sympathetic innervation.Life science alliance · 2026Article
- Sex-dependent and compartment-specific macrophage accumulation associates with glomerular injury in BTBR ob/ob mice.Pflugers Archiv : European journal of physiology · 2026Article
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- The associations between cardiometabolic index and mortalities in chronic kidney disease.Medicine · 2026Article
- Association between serum glucose/potassium ratio and acute kidney injury in patients with traumatic brain injury: based on MIMIC-IV database.Journal of global health · 2026Article
- The Vicious Cycle of Diabetic Kidney Disease, Vitamin D Deficiency, and Arterial Hypertension.Healthcare (Basel, Switzerland) · 2026Review
- Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM.American journal of preventive cardiology · 2026Article
- Protective Effects of Chitosan and Rosuvastatin on Renal Structure and Lipid Metabolism in Rabbits Fed a High-Fat Diet.Medicina (Kaunas, Lithuania) · 2026Article
- Review
- The role of gut dysbiosis in endocrine and metabolic derangements of chronic kidney disease: mechanisms, controversies, and future perspectives.Frontiers in endocrinology · 2026Review
- Obesity-Related Insulin Resistance Indices and CKD Risk in Patients with Diabetes and Coronary Heart Disease: A Multicenter Cohort Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- High Estimated 24-Hour Urinary Sodium Excretion is Associated With Metabolic Syndrome and Its Phenotypes: Tehran Lipid and Glucose Study.Journal of nutrition and metabolism · 2026Article
- The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.Acta biochimica Polonica · 2026Review
- Gastrodin alleviates high fructose-induced podocyte mitochondria-mediated apoptosis by inhibiting NLRP6 to facilitate TRIM7-triggeredInternational journal of biological sciences · 2026Article
- Gut Microbiota Dysbiosis and Metabolite Imbalance Mediate Diabetic Kidney Disease Inflammation: Mechanisms and Intervention Strategies Targeting Gut-Kidney Axis and NF-κB/NLRP3 Pathways.Journal of inflammation research · 2026Review
- The triglyceride-glucose index in chronic kidney disease: a narrative review.Frontiers in nutrition · 2026Review
- Effect of Doum (Frontiers in nutrition · 2026Article
- Metabolic syndrome and kidney dysfunction: emerging molecular and cellular mechanisms at the metabolic-renal interface.Frontiers in endocrinology · 2026Review
- Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) includes visceral obesity, hyperglycemia, dyslipidemia, and hypertension. The prevalence of MetS is 20-25%, which is an important risk factor for chronic kidney disease (CKD). MetS causes effects on renal pathophysiology, including glomerular hyperfiltration, RAAS, microalbuminuria, profibrotic factors and podocyte injury. This review compares several criteria of MetS and analyzes their differences. MetS and the pathogenesis of CKD includes insulin resistance, obesity, dyslipidemia, inflammation, oxidative stress, and endothelial dysfunction. The intervention of MetS-related renal damage is the focus of this article and includes controlling body weight, hypertension, hyperglycemia, and hyperlipidemia, requiring all components to meet the criteria. In addition, interventions such as endoplasmic reticulum stress, oxidative stress, gut microbiota, body metabolism, appetite inhibition, podocyte apoptosis, and mesenchymal stem cells are reviewed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.